LIFEVALVE
Living autologous heart valves for minimally invasive implantable procedures
| Coordinatore | UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 16˙062˙828 € |
| EC contributo | 9˙876˙352 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-11-01 - 2015-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | coordinator | 2˙470˙000.00 |
| 2 |
DEUTSCHES HERZZENTRUM BERLIN
Organization address
address: Augustenburger Platz 1 contact info |
DE (BERLIN) | participant | 3˙142˙372.00 |
| 3 |
TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
NL (EINDHOVEN) | participant | 1˙784˙000.00 |
| 4 |
XELTIS BV
Organization address
address: DE LISMORTEL R2 06 CAT BUILD 31 contact info |
NL (Eindhoven) | participant | 1˙146˙000.00 |
| 5 |
XELTIS AG
Organization address
address: MUHLEBACHSTRASSE 26 contact info |
CH (ZURICH) | participant | 850˙500.00 |
| 6 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 215˙480.00 |
| 7 |
pfm Produkte fur die Medizin AG
Organization address
address: Wankelstr. 60 contact info |
DE (Cologne) | participant | 201˙000.00 |
| 8 |
DEBRECENI EGYETEM
Organization address
address: EGYETEM TER 1 contact info |
HU (DEBRECEN) | participant | 67˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.'
Introduzione (Teaser)
Approximately 1 in 100 children is born with a congenital heart defect. European scientists are developing heart valves that grow with the child and can be implanted using a minimally invasive procedure.